ICON is a global provider of outsourced drug development services to biopharma, medical device, government, biosimilar and generic organisations. We offer a full range of clinical, consulting and commercial services that range from trial design to full study execution, and from clinical to post-market commercialisation. Our services are supported by in-depth therapeutic and regulatory expertise and market-leading technology and analytics. We are the only full service CRO that offers the knowledge, software and systems for adaptive trials.
With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,300 employees. Further information is available at www.iconplc.com